HLS HLS Therapeutics Inc.
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders and cardiovascular disease in Canada, the United States, and inter…
Industry Peers
Drug Manufacturers - Specialty & Generic| Headline | Source | Time |
|---|---|---|
Older | ||
 HLS Therapeutics (TSX:HLS) Stock Fair Value Rises After Analysts Turn More Positive Price targets on HLS Therapeutics have widened, with the most optimistic research pointing to C$8 while more cautious views sit near C$5. This spread reflects the recent shift in analyst commentary, where some see an inflection point for growth and cash generation, while others prefer to wait for more proof in upcoming quarters. As you read on, you will see what is driving these views and how to track the evolving story around HLS Therapeutics. Stay updated as the Fair Value for HLS... | ||
HLS Therapeutics Inc (HLTRF) (Q2 2026) Earnings Call Highlights: Cardiovascular Portfolio ... Strong Naleo uptake and Vascepa growth drive robust performance, offset by launch-related investments impacting near-term margins | ||
 HLS Therapeutics Q2 Earnings Call Highlights HLS Therapeutics (TSE:HLS) reported second-quarter fiscal 2026 revenue growth as its cardiovascular portfolio expanded 25% year over year, led by continued gains for Vascepa and the first full quarter of sales for newly launched NILEMDO. Total revenue for the quarter ended June 30 was $14.7 million | ||